Drugs giant GlaxoSmithKline and German biotech firm CureVac have struck a €150m (£130m) deal to develop next-generation COVID-19 vaccines that target several variants of the virus in one product.
Full ArticlePlan to develop new vaccine that targets COVID-19 variants in one jab
Sky News
0 shares
2 views
You might like
Related news coverage
Vaccine Nationalism Is A Multilateral, Neocolonial Failure – OpEd
Eurasia Review
In the coming months, vaccine nationalism is likely to compound COVID-19 economic damage and penalize more lives. It reflects the..